Parexel Names Clare Grace to Newly-Created Role of Chief Patient Officer

January 4, 2021

Appointment is a first for a top-tier CRO; reinforces Parexel's patients-first focus in clinical research

BOSTON and DURHAM, N.C. – Jan. 4, 2021 – Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced the appointment of Clare Grace, Ph.D., as the company's first Chief Patient Officer. The appointment reflects the role of the patient as central to the company's mission of keeping patients at the heart of all clinical trial activity.

The appointment of a Chief Patient Officer is a first for a top-tier CRO, further demonstrating Parexel's commitment to elevate the patient perspective so that their unique needs can be used to shape the conduct of future clinical studies.

"Patients are at the heart of everything we do," said Sy Pretorius, MD, Chief Medical and Scientific Officer at Parexel. "Clare's proven track record of delivering innovative patient and site engagement programs make her the perfect candidate to lead our patient-focused mission. We are pleased to welcome her to Parexel as we further evolve our support for patients and investigative sites worldwide."

"I am thrilled to join Parexel and to continue to champion the company's patient focus to ultimately improve clinical trials and accelerate the delivery of new therapies for patients around the world," said Dr. Grace. "I look forward to working closely with our sites and technology partners to improve the patient experience and to further infuse the patient perspective across all studies and further enhance our ability to deliver innovative clinical trial solutions that meet our customers' needs."

With more than 20 years of experience in the CRO and biopharmaceutical industries, Dr. Grace was recognized in 2018 by *PharmaVoice* as one of the top 100 most inspirational leaders in the pharmaceutical industry. She earned a doctorate in Molecular Oncology from the University of Manchester Institute of Science and Technology and a bachelor's degree in applied biochemistry from Liverpool John Moores University, both in England. Dr. Grace is active in several global and national-level advisory groups, including the Society for Clinical Research Sites (SCRS) and the SCRS Leadership Council.

As Chief Patient Officer for Parexel, Dr. Grace will lead global patient advocacy and site efforts, including patient engagement strategies and efforts to enhance clinical trial diversity as well as new, innovative approaches to help teams and customers work more effectively with investigative sites. Most recently she served as Vice President, Site & Patient Access at Syneos Health, formerly INC Research, where she oversaw all departments responsible for patient engagement, feasibility, site identification, strategic site relations and investigator payments. Her experience also includes senior-level patient and site-focused leadership roles with PPD, Astra Zeneca and Antisoma.

About Parexel

Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life science and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. Parexel was named "Best Contract Research Organization" in December 2020 by an independent panel for ***Informa Pharma Intelligence.*** For more information, visit our **website** and follow us on **LinkedIn**, **Twitter** and **Instagram**.

CONTACT:

Parexel
Lori Dorer
+1 513 496 8121
Lori.dorer@parexel.com

W2O
Lindsay LeCain
+1 508 259 9521
parexelpr@w2ogroup.com